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Heart diseases are a signiﬁcant cause of morbidity and mortality in newborns. Diagnostic methods are often not suﬃcient
or, in many cases, cannot be used. There is a great advance in medical knowledge concerning biomarkers in the diagnosis
of circulatory system in adult patients. Among them, cardiac troponins play the main role. In current literature, there is not
enough data concerning the possibility of using them in neonatal cardiac diagnostics. Aim of the Study. To evaluate diagnostic
usefulness of cTnT in correlation with other markers of circulatory failure and myocardial damage in newborns with heart
defects. Patients and Methods. The study involved 83 newborns up to 46 weeks of postmenstrual age. The exclusion criteria were
severe perinatal asphyxia and presence of severe noncardiac diseases. Patients were divided into 2 main groups: group I—54
patients with congenital heart defects (CHDs), and group II (control)—29 healthy neonates. All patients underwent detailed
examination of circulatory system. Cardiac troponin T (cTnT) concentrations were evaluated by Roche CARDIAC T Quantitive
test. Results. Performed studies revealed that cTnT levels in newborns with heart pathology were signiﬁcantly higher than in
healthy ones. However, cTnT concentrations in patients with CHD did not correlate with clinical symptoms of heart failure, nor
with echocardiographic markers of LV function. Type of heart defect did not inﬂuence cTnT levels as well. Only hemodynamic
signiﬁcance evaluated by echocardiography inﬂuenced the cTnT levels with statistical signiﬁcance. Conclusions. (1) Statistically
signiﬁcant diﬀerences in cTnT levels between newborns with heart defects and healthy subjects were shown. (2) CTnT levels in
newborns with heart defects refer only to hemodynamic signiﬁcance of the defect.
1.Introduction
Heart diseases leading to circulatory failure are a signiﬁcant
cause of morbidity and mortality in newborns [1]. Diagnosis
of early stages heart failure in newborn is diﬃcult because
clinical symptoms are nonspeciﬁc. The diagnostic methods
indicatingcardiacdamageareoftennotsuﬃcientor,inmany
cases, cannot be used due to high technical requirements
or their invasive nature [2]. It is necessary to look for non-
invasive markers that would enable wider diagnosis of heart
muscle damage and cardiac insuﬃciency risk in neonates.
Cardiac troponins are protein components of the tro-
pnin-tropomyosin complex in myocardium. Since troponins
do not occur in extracellular space, their appearance in se-
rum is sensitive and speciﬁc marker of myocardium damage
[3]. Troponins appear in blood in 2 to 4 hours after insult,
peak in about 12h and then remain elevated for 7–10 days
[3, 4].
Sensitivity of both cTnT and cTnI in the diagnosis of
myocardial damage is clinically almost equal. They diﬀer in
intracellular compartments, biological half-life, and molecu-
lar weight [5]. There are also diﬀerences in the standardiza-
tion and availability of commercial troponin kits. Absolute
values of gained results are often incomparable, however, di-
agnostic features of particular methods are similar [6].
Cardiac troponins (cTn) are biochemical markers of my-
ocardial injury with unquestionable signiﬁcance in diag-
nostic strategy in adults [3, 7–11]. However, their role in
diagnostics in neonates has not been fully explored yet.
Cardiac troponins have not been used routinely in neonates
because of insuﬃcient data conﬁrming their clinical utility
in this age group. Studies conducted in other groups conﬁrm2 The Scientiﬁc World Journal
the usefulness of troponins in clinical situations that lead to
cardiomiocytes injury, including cardiac inﬂammatory dis-
eases [2, 4, 5, 12–14]. In literature, the following applications
of cTn in pediatrics are mentioned: acute myocarditis, heart
arrhythmias, perinatal asphyxia in newborns, perioperative
myocardial injury in patients operated for congenital heart
diseases, drug-induced cardiotoxity, and cardiac transplan-
tation [4, 5, 14].
2 .T h eA imo ft h eS t ud y
Was to evaluate the diagnostic usefulness of cTnT measure-
mentsincorrelationwithothermarkersofcirculatoryfailure
and myocardial damage in newborns with congenital heart
defects.
3. Patientsand Methods
The study involved 83 newborns up to 46 weeks of postmen-
strual age. The gestational age of studied newborns was
25–42 weeks, mean: 38 weeks. Chronological age (in days
from the date of birth) was 6–135 days, mean: 21 days.
Postmenstrual age was 34–46 weeks, mean: 41 weeks. Birth
weight of studied newborns was 585–5400g, mean: 3137g.
The exclusion criteria were severe perinatal asphyxia (Apgar
scale ≤ 4 points in 1st and 5th minute) and patients with
signs of severe noncardiac diseases.
All patients underwent detailed subjective and physical
examination. In patients with abnormalities in circulatory
systemechocardiographyandelectrocardiographictestswere
performed. On the basis of performed examination, patients
were divided into 2 main groups: group I—54 patients with
congenital heart defects (CHDs), and group II (control)—
29 healthy neonates up to 46 weeks of postmenstrual
age. Newborns with CHD were divided into following
subgroups: group Ia—with simple shunts and group Ib—
with combined heart defects (Table 1). Patients in group
I were also divided according to hemodynamic signiﬁ-
cance of the heart defect evaluated in echocardiography.
Hemodynamic signiﬁcance was evaluated on the base of
echocardiographic parameters such as right ventricle and/or
right atrium enlargement, accelerated blood ﬂow in main
pulmonary artery (MPA), and extension of MPA, pres-
ence of tricuspid regurgitation, extension of pulmonary
veins. The particular criteria of hemodynamic signiﬁcance
depended on the type of heart defect. The following
subgroups were stated: group Ii—with hemodynamic sig-
niﬁcant defect and group In—without hemodynamic sig-
niﬁcance. The comparison of clinical variables between par-
t i c u l a rg r o u p si sp r e s e n t e di nT a b l e s4 and 5.
Each newborn with cardiac abnormality had the fol-
lowing examinations performed: echocardiography with left
ventricle ejection fraction (EF LV) evaluation, chest X-ray,
and blood pressure measurement. All patients were also
evaluated with Ross’es heart failure in infants classiﬁcation
[15] and with Reithmann’s pediatric heart failure score [16].
Basic laboratory tests were performed in each newborn. The
study protocol was approved by the Ethics Committee of
Medical University of Lublin.
Troponin T levels were evaluated in 150µL of whole
blood by Roche CARDIAC T Quantitative test (third gen-
eration; Roche Diagnostics). The Roche CARDIAC T quan-
titive test includes two monoclonal antibodies speciﬁc for
cardiac troponin T. Measuring range of the test is 0.03
to 2ng/mL. The results are not inﬂuenced by hyper-
bilirubinemia (bilirubin <20mg/dL), hemolysis nor lipemia
(triglicerydes <440mg/dL). Blood samples were collected
into standardized heparinized tubes. The obtained results,
afterchecking thenormality ofdistribution, werestatistically
analyzed by the use of appropriate test with Statistica 9.0
packet.Right-handedasymmetryofcertaindistributionswas
eliminated by the use of logarithmic transformation. De-
pendency analysis was performed based on Pearson’s linear
correlation coeﬃcient (r) or Spearman’s (R) rank correlation
test and t-test signiﬁcance of the correlation coeﬃcient in
the population. The results were concerned as statistically
signiﬁcant when P<0.05.
4. Results
Performed studies revealed that cTnT levels in newborns
withheartpathologyweresigniﬁcantlyhigherthaninhealth-
yo n e s( P = 0.035, Figure 1, Table 2). However, cTnT
concentrations in patients with CHD did not correlate with
clinical symptoms of heart failure evaluated with Ross’es
scale (R = 0.095 and P = 0.493) as well as with
Reithmann’s classiﬁcation (R = 0.076, P = 0.493). Cardiac
TnT concentrations also did not correlate with echocardio-
graphic markers of LV function, nor with the type of heart
defect. The obtained results revealed that only hemodynamic
signiﬁcance of heart defect evaluated by echocardiography
inﬂuenced the cTnT levels with statistical signiﬁcance (P =
0.048, Table 3).
5. Discussion
Cardiac troponins are highly speciﬁc cardiac markers, ex-
tremely sensitive, and valuable in diagnostics of myocardial
necrosis [17, 18]. Sobki et al. [19] in their paper demon-
strated that troponins are very highly sensitive and speciﬁc
for myocardial injury. Other studies showed that troponin
elevations may occur in diﬀerent cardiac pathologies, not
only in ischemic heart disease [18]. According to studies
conducted on adult patients, increased oxygen demand in
myocardium and the increase of cardiac troponins serum
concentration occur in clinical situations like: arrhythmias
(atrial ﬁbrillation, supraventricular tachycardia, etc.), in
chronic and acute heart failure, or in myocarditis [17].
The accurate mechanisms responsible for the elevation of
troponin serum concentration in diseases other than acute
coronary syndromes remain in the course of research [18].
According to data from literature, elevated cTn concentra-
tions in cardiac insuﬃciency are connected with the decrease
of left ventricular ejection fraction and correlate with the
severity of symptoms and with worse prognosis [17]. WhileThe Scientiﬁc World Journal 3
Table 1: Characteristic of heart defects in group I patients.
Division of heart defects Group I (N = 54) Type of defect Number of patients
Hemodynamic signiﬁcant
defects (GroupIi) N = 29
Simple shunts(GroupIa)
N = 16
ASD + VSD 10
ASD + VSD + PDA 2
ASD + PDA 2
PDA 1
ASD 1
Combined heart defects
(GroupIb) N = 13
CAVC 5
FT4 2
PS + ASD 1
CoA + ASD 1
TA 1
L-TGA +VSD + PS 1
DORV + ASD 1
S A+P S+A S D+P D A 1
Defects without
hemodynamic signiﬁcance
(GroupIn) N = 25
Simple shunts (GroupIa)
N = 24
ASD 11
ASD + PDA 7
ASD + VSD 4
ASD + VSD + PDA 2
Combined heart defects
(GroupIb) N = 1 PS + ASD 1
N: number of patients
ASD: atrial septum defect
VSD: ventricular septum defect
PDA: persistent ductus arteriosus
CoA: aortic coarctation
PS: pulmonary stenosis
DORV: double outlet left ventricle
TA: truncus arteriosus
TGA: transposition of great arteries
SA: aortic stenosis.
Table 2: Number of patients with particular cTnT concentration
ranges in studied groups.
cTnT (ng/mL)
Newborns
with heart
defects group I
(N = 54)
Control group
group II
(N = 29)
Statistical
signiﬁcance
<0,03 20 6
P = 0,035 0,03–0,1 24 22
0,1–2,0 10 1
N: number of patients.
these biomarkers were widely studied in adult patients,
with structurally normal hearts, it is unknown if the results
correlate with heart failure in newborns and infants with
congenital heart defects. Typically, cardiac insuﬃciency in
adults is usually connected with coronary disease, whereas
in children heart failure is rather complication of structural
abnormalities or primary myocardial dysfunction [20].
Shahetal.[20]intheirstudymadeanattempttoevaluate
whether serum cTnI concentrations in children with func-
tionally single-chamber heart may be used as biomarker of
heart failure. The study included 29 children at the age of
1 month to 7 years, with functionally single-chamber heart.
No diﬀe r e n c e si nc T n Ic o n c e n t r a t i o n sw e r ef o u n db e t w e e n
patients with functionally one ventricle and heart failure and
those without cardiac insuﬃciency. In most patients, cTnI
concentrations were undetectable.
Similarly,onthebasisoftheresultsobtainedinourstudy,
no diﬀerence was stated between serum cTnT concentra-
tions and clinical exponents of heart failure. The obtained
results did not show correlation with clinical symptoms of
heart failure evaluated with Ross’es heart failure in infants
classiﬁcation, nor with Reithmann’s pediatric heart failure
score. Heart failure is more frequently observed in neonates,
especially in preterms [21]. In the available literature, there
was no study evaluating correlation between clinical heart
failure symptoms and cardiac troponins concentrations
in newborns with congenital heart defects. The obtained
results, similar as data from literature concerning older
children with CHD, conﬁrm that in opposite to adults, car-
diac troponins concentration in pediatric patients does not
correlate with the severity of clinical heart failure symptoms.
Most probably, this follows diﬀerent etiopathogenesis of
heart failure in children and adults. Although, Mu˜ niz [22]
in his paper presented a case report of patient at the age of
9 weeks with combined congenital heart defect and chronic4 The Scientiﬁc World Journal
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Figure 1: Number of patients with particular cTnT concentration
ranges in studied groups.
heart failure, in whom signiﬁcantly elevated troponin levels
were observed, however, it was only a single report. The
author suggests that there is an increased risk of arrhythmia
or heart function deterioration in infants with elevated heart
enzymes.
At present, echocardiography is the best tool to evaluate
heart structure and myocardial contractility [21]. According
to data from literature, evaluating serum cardiac troponin
concentrations as markers combined with results of echocar-
diography may largely facilitate making clinical decisions
[21]. The available literature showed that cardiac troponins
may also serve as useful complement in evaluation of respi-
ratory distress syndrome and perinatal asphyxia in newborns
[23]. In one of the studies, cTnT serum concentrations
were correlated with echocardiographic measurements in
pretermnewbornsintheir12thhouroflife[24].Theauthors
showed signiﬁcant negative correlation between cTnT and
echocardiographic markers of myocardial function.
In our studies, no correlation between shortening frac-
tion (SF) evaluated by echocardiography and cTnT concen-
tration in newborns with CHD was observed. The above
result is diﬃcult to be referred with data from the literature,
as yet only one study led by EL-Khuﬀash et al. [24] showed
correlation between SF and cardiac troponins concentration
in newborns. However, the mentioned study involved only
preterms born in 26.1–29.5 weeks of gestational age, with
structurally normal hearts, and troponin concentration
evaluation was performed in the ﬁrst day of life. Possibly,
the noncompliance in our results and results of the cited
study is due to diﬀerences between the groups of studied
patients. On the other hand, SF is not a reliable indicator
of left ventricle systolic function in newborns, because of
the typical adaptation period high blood pressure in right
ventricle, which inﬂuences septum movements [25]. In case
of congenital structural heart defects, this discrepancy may
be even more strongly expressed.
Structural heart defects are the most often inborn mal-
formations diagnosed in the ﬁrst year of life [21]. Studies
conducted in adults with heart defects showed that mean
cTnI concentration was higher in patients with aortic valve
pathology compared with control group [26]. Also el-
evated pulmonary blood pressure might be connected with
increased cTnI serum concentrations [26]. In available
literature, there is a very small number of studies evaluating
troponin concentrations in pediatric patients with heart
defects. In order to determine the inﬂuence of congenital
or acquired heart defects on cardiac troponin serum con-
centrations, Hirsch et al. [27] evaluated cTnI levels in two
groups of children. Group A was represented by pediatric
patients without diagnosed heart disease and stable patients
with known congenital or acquired cardiac abnormalities.
Group B was created from patients admitted to Intensive
CareUnit:withnormalECHOresults,withabnormalECHO
results, or after chest injury. The mentioned authors stated
that cTnI levels are generally not elevated in children with
stable heart disease or in children with systemic diseases.
Onthebasisofourstudies,itwasfoundthatcTnTserum
concentration is statistically signiﬁcantly higher in newborns
with CHD compared to patients from the control group. In
available literature, it is diﬃcult to ﬁnd studies concerning
troponin concentrations in neonatal patients with heart
defects. One of the papers [23] showed that cTnT concen-
trations in newborns with persisted ductus arteriosus (PDA)
signiﬁcantly correlated with the arterial duct diameter, the
shunt velocity, and end diastolic volume in descending aorta.
The authors concluded that cTnT may be a useful marker of
PDA signiﬁcance and reaction to treatment, as it correlates
with echocardigraphic PDA markers. Elevated cTnT concen-
tration may reﬂect the potential myocardial damage caused
by the presence of PDA. Stealing of oxygenated blood by
arterial duct can inﬂuence the coronary ﬂow, and potentially
lead to ischemia [23].
Inanotherresearch,conductedbyEL-Khuﬀashetal.[24]
on group of preterm newborns with PDA, cTnT evaluation,
and ECHO examination were performed in the ﬁrst day
of life. Signiﬁcant negative correlation was found between
cTnT and echocardiographic markers of left ventricle (LV),
including SF LV. Correlation between PDA diameter and
cTnT was not conﬁrmed. This was the only study as yet in
which correlation between cTnT and EF LV in newborns was
found. According to the authors, the above results may have
practical application in indirect evaluation of myocardial
function in newborns when echocdiography is not available.
In the same paper, it was shown that cTnT did not depend
on cardiac volume load.
In available literature, there were no other studies found
concerning cardiac troponin concentrations in CHD inThe Scientiﬁc World Journal 5
Table 3: Troponin T concentration categories in dependence of heart defect hemodynamic signiﬁcance.
Hemodynamic signiﬁcance group I (N = 54) Statistical signiﬁcance
TnT (ng/mL) Signiﬁcant (group Ii) N = 29 Not signiﬁcant(group In) N = 25
<0,03 7 13
P = 0,048 0,03–0,1 14 10
0,1–2,0 82
N: number of patients.
Table 4: Comparison of clinical signs of heart failure evaluated by
the Rosse’s heart failure in infants classiﬁcation in studied groups.
Group Class Number of patients
I( n = 54)
Ii (n = 29)
I2 2
II 2
III 2
IV 3
In (n = 25) I 25
II (n = 49) I 49
Table 5:Comparisonofclinicalsignsofheartfailureevaluatedwith
the Reithmann’s pediatric heart failure score.
Group Score (points) Number of patients
I( n = 54)
Ii (n = 29)
0–2 24
3–6 2
>63
In (n = 25) 0–2 25
II (n = 49) 0–2 49
newborns before cardiosurgeric treatment. In our previous
study, cTnI concentrations were evaluated in 41 newborns
at the age of 7–28 days with CHD [28]. No diﬀerences were
found in cTnI concentration in studied patients depending
on type of heart defect (simple or combined). However,
elevatedcTnIlevelswerefoundinnewbornswithpulmonary
hypertension (HP), secondary to structural heart defect
compared to group without HP and the diﬀerence was close
to statistical signiﬁcance. Results of the present study does
not conﬁrm this observation, as no signiﬁcant correlation
was found between cTnT concentration and features of HP
in newborns with CHD.
The results of our study conﬁrmed that although cTnT
concentrations are signiﬁcantly higher in newborns with
CHD compared to healthy ones, however, no signiﬁcant
diﬀerence was found depending on the type of the defect.
In newborns with isolated left-to-right shunt defects, no
signiﬁcant correlation was observed between cTnT concen-
tration and shunt velocity evaluated by echocardiography.
Also, no signiﬁcant correlation was found between cTnT
concentration and the diameter of septal defect or PDA.
However, the obtained results showed signiﬁcant correlation
between cTnT concentration and hemodynamic signiﬁcance
of heart defect evaluated on the basis of echocardiographic
evaluation. Heart defects more hemodynamically signiﬁcant
carry greater risk of heart failure development and necessity
to start appropriate treatment as soon as possible. The
correlation between cTnT concentration and hemodynamic
signiﬁcance of CHD creates potential possibility for above
biomarker to be used for early detection of newborns with
signiﬁcant heart defects, who need urgent cardiology consul-
tation.
6. Conclusions
(1) Statistically signiﬁcant diﬀerences in cTnT levels
between newborns with heart defects and healthy
subjects were shown.
(2) Cardiac TnT concentrations in newborns with CHD
does nor correlate with clinical signs of heart failure
nor with echocardigraphic markers of LV function.
(3) Cardiac TnT concentrations in newborns with CHD
does not depend on the type of the defect.
(4) The statistically signiﬁcant correlation was found be-
tween cTnT concentration and hemodynamic signif-
icance of CHD in examined newborns.
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